Literature DB >> 11122793

The biology of human epidermal growth factor receptor 2.

S Sundaresan1, E Penuel, M X Sliwkowski.   

Abstract

Our understanding of the normal signaling mechanisms and functions of human epidermal growth factor receptor 2 (HER2) and other members of the HER family, namely epidermal growth factor receptor, HER3, and HER4, is growing rapidly. Activation of these receptors results in a diverse array of signals through the formation of homodimeric and heterodimeric receptor complexes; HER2 is the preferred dimerization partner for the other HERs. These oligomeric receptor complexes activate distinct signaling pathways, such as the Ras-MAPK and PI3-kinase pathways. These, in turn, affect various cellular processes. Recent gene deletion experiments in mice point to an important role for HER2 in cardiac and neural development, and evidence from other studies indicates that HER2 is involved in normal breast growth and development. Thus, HER2 is a key component of a complex signaling network that plays a critical role in the regulation of tissue development, growth, and differentiation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11122793     DOI: 10.1007/s11912-999-0005-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  60 in total

1.  Expression of neuregulins and their putative receptors, ErbB2 and ErbB3, is induced during Wallerian degeneration.

Authors:  S L Carroll; M L Miller; P W Frohnert; S S Kim; J A Corbett
Journal:  J Neurosci       Date:  1997-03-01       Impact factor: 6.167

2.  Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein.

Authors:  S L Sierke; K Cheng; H H Kim; J G Koland
Journal:  Biochem J       Date:  1997-03-15       Impact factor: 3.857

Review 3.  Molecular regulation of atrioventricular valvuloseptal morphogenesis.

Authors:  L M Eisenberg; R R Markwald
Journal:  Circ Res       Date:  1995-07       Impact factor: 17.367

4.  Epidermal growth factor receptor and c-erbB-2 expression in normal breast tissue during the menstrual cycle.

Authors:  A Gompel; A Martin; P Simon; D Schoevaert; G Plu-Bureau; D Hugol; J Audouin; E Leygue; J B Truc; P Poitout
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts.

Authors:  Y Kokai; J N Myers; T Wada; V I Brown; C M LeVea; J G Davis; K Dobashi; M I Greene
Journal:  Cell       Date:  1989-07-28       Impact factor: 41.582

6.  Identification of autophosphorylation sites of HER2/neu.

Authors:  R Hazan; B Margolis; M Dombalagian; A Ullrich; A Zilberstein; J Schlessinger
Journal:  Cell Growth Differ       Date:  1990-01

7.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.

Authors:  A L Schechter; D F Stern; L Vaidyanathan; S J Decker; J A Drebin; M I Greene; R A Weinberg
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

8.  ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family.

Authors:  D L Falls; K M Rosen; G Corfas; W S Lane; G D Fischbach
Journal:  Cell       Date:  1993-03-12       Impact factor: 41.582

9.  Synapse-associated expression of an acetylcholine receptor-inducing protein, ARIA/heregulin, and its putative receptors, ErbB2 and ErbB3, in developing mammalian muscle.

Authors:  L M Moscoso; G C Chu; M Gautam; P G Noakes; J P Merlie; J R Sanes
Journal:  Dev Biol       Date:  1995-11       Impact factor: 3.582

10.  Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.

Authors:  C Wallasch; F U Weiss; G Niederfellner; B Jallal; W Issing; A Ullrich
Journal:  EMBO J       Date:  1995-09-01       Impact factor: 11.598

View more
  10 in total

1.  Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer.

Authors:  Maribeth Maher
Journal:  P T       Date:  2014-03

2.  MKP1 mediates resistance to therapy in HER2-positive breast tumors.

Authors:  Demet Candas; Jian Jian Li
Journal:  Mol Cell Oncol       Date:  2015-01-23

Review 3.  The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis.

Authors:  S A Eccles
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

4.  Interleukin-6 is required for Neuregulin-1 induced HER2 signaling in lung epithelium.

Authors:  Rangnath Mishra; Daniel G Foster; James H Finigan; Jeffrey A Kern
Journal:  Biochem Biophys Res Commun       Date:  2019-04-16       Impact factor: 3.575

5.  Neuroprotective effects of neuregulin-1 on B35 neuronal cells following ischemia.

Authors:  DaJoie R Croslan; Matthew C Schoell; Gregory D Ford; John V Pulliam; Alicia Gates; Ceilessia M Clement; Adalynn E Harris; Byron D Ford
Journal:  Brain Res       Date:  2008-03-04       Impact factor: 3.252

6.  Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.

Authors:  Kristina W Thiel; Luiza I Hernandez; Justin P Dassie; William H Thiel; Xiuying Liu; Katie R Stockdale; Alissa M Rothman; Frank J Hernandez; James O McNamara; Paloma H Giangrande
Journal:  Nucleic Acids Res       Date:  2012-03-30       Impact factor: 16.971

7.  Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters.

Authors:  Amit Garg; Jing Li; Emma Clark; Adam Knott; Timothy J Carrothers; Jean-François Marier; Javier Cortés; Michael Brewster; Jennifer Visich; Bert Lum
Journal:  Cancer Chemother Pharmacol       Date:  2013-09-03       Impact factor: 3.333

8.  MTSS1 and SCAMP1 cooperate to prevent invasion in breast cancer.

Authors:  Jayakumar Vadakekolathu; Shaymaa Ismael Kadhim Al-Juboori; Catherine Johnson; Anne Schneider; Magdalena Elżbieta Buczek; Anna Di Biase; Alan Graham Pockley; Graham Roy Ball; Desmond George Powe; Tarik Regad
Journal:  Cell Death Dis       Date:  2018-03-01       Impact factor: 8.469

Review 9.  ErbB Proteins as Molecular Target of Dietary Phytochemicals in Malignant Diseases.

Authors:  Alexandru Filippi; Oana-Alina Ciolac; Constanța Ganea; Maria-Magdalena Mocanu
Journal:  J Oncol       Date:  2017-02-13       Impact factor: 4.375

10.  Current progress of RNA aptamer-based therapeutics.

Authors:  Jiehua Zhou; Maggie L Bobbin; John C Burnett; John J Rossi
Journal:  Front Genet       Date:  2012-11-02       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.